N-3-substituted imidazoquinazolinones: Potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction

David Rotella, Zhong Sun, Yeheng Zhu, John Krupinski, Ronald Pongrac, Laurie Seliger, Diane Normandin, John E. Macor

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity relative to sildenafil may result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE-associated adverse effects. This paper describes the discovery of 14, a PDE5 inhibitor with improved potency and selectivity in vitro compared to sildenafil. This compound shows activity in a functional assay of erectile function comparable to that of sildenafil.

Original languageEnglish
Pages (from-to)1257-1263
Number of pages7
JournalJournal of Medicinal Chemistry
Volume43
Issue number7
DOIs
StatePublished - 6 Apr 2000

Fingerprint

Phosphodiesterase 5 Inhibitors
Erectile Dysfunction
Isoenzymes
Incidence
Sildenafil Citrate

Cite this

Rotella, David ; Sun, Zhong ; Zhu, Yeheng ; Krupinski, John ; Pongrac, Ronald ; Seliger, Laurie ; Normandin, Diane ; Macor, John E. / N-3-substituted imidazoquinazolinones : Potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. In: Journal of Medicinal Chemistry. 2000 ; Vol. 43, No. 7. pp. 1257-1263.
@article{fecd3b9bc13041f881405e1bcbfe5295,
title = "N-3-substituted imidazoquinazolinones: Potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction",
abstract = "Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity relative to sildenafil may result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE-associated adverse effects. This paper describes the discovery of 14, a PDE5 inhibitor with improved potency and selectivity in vitro compared to sildenafil. This compound shows activity in a functional assay of erectile function comparable to that of sildenafil.",
author = "David Rotella and Zhong Sun and Yeheng Zhu and John Krupinski and Ronald Pongrac and Laurie Seliger and Diane Normandin and Macor, {John E.}",
year = "2000",
month = "4",
day = "6",
doi = "10.1021/jm000081+",
language = "English",
volume = "43",
pages = "1257--1263",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "7",

}

N-3-substituted imidazoquinazolinones : Potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. / Rotella, David; Sun, Zhong; Zhu, Yeheng; Krupinski, John; Pongrac, Ronald; Seliger, Laurie; Normandin, Diane; Macor, John E.

In: Journal of Medicinal Chemistry, Vol. 43, No. 7, 06.04.2000, p. 1257-1263.

Research output: Contribution to journalArticle

TY - JOUR

T1 - N-3-substituted imidazoquinazolinones

T2 - Potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction

AU - Rotella, David

AU - Sun, Zhong

AU - Zhu, Yeheng

AU - Krupinski, John

AU - Pongrac, Ronald

AU - Seliger, Laurie

AU - Normandin, Diane

AU - Macor, John E.

PY - 2000/4/6

Y1 - 2000/4/6

N2 - Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity relative to sildenafil may result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE-associated adverse effects. This paper describes the discovery of 14, a PDE5 inhibitor with improved potency and selectivity in vitro compared to sildenafil. This compound shows activity in a functional assay of erectile function comparable to that of sildenafil.

AB - Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity relative to sildenafil may result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE-associated adverse effects. This paper describes the discovery of 14, a PDE5 inhibitor with improved potency and selectivity in vitro compared to sildenafil. This compound shows activity in a functional assay of erectile function comparable to that of sildenafil.

UR - http://www.scopus.com/inward/record.url?scp=0034611619&partnerID=8YFLogxK

U2 - 10.1021/jm000081+

DO - 10.1021/jm000081+

M3 - Article

C2 - 10753463

AN - SCOPUS:0034611619

VL - 43

SP - 1257

EP - 1263

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 7

ER -